H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Lexicon (LXRX) to $6 from $10 and keeps a Buy rating on the shares. The firm removed Zynquista from its projections, pending FDA visibility on the path forward. It is too risky to handicap the outcome of the upcoming FDA action date in December, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- FDA panel votes 11-3 that Lexicon’s Zynquista benefits do not outweigh risks
- FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
- Lexicon announces new analysis of Phase 3 SCORED trial
- Lexicon’s LX9211 progressing ahead of schedule, says H.C. Wainwright
- Lexicon completes screening in Phase 2B progress study of LX9211